Researchers put overdiagnosis of idiopathic intracranial hypertension (IIH) down to inaccurate ophthalmoscopic examination in headache patients and wrongly suspecting the condition in young obese women with headaches.
Central Serous Chorioretinopathy: Risk Factors Identified
H pylori infection, steroid use, disturbed sleep, autoimmune disease, psychopharmacologic medication use, and type A behavior were among possible risk factors for central serous chorioretinopathy. Medscape Medical News
Uncategorized
FDA gives greenlight for phase 2 study of travoprost with iDose delivery system
The FDA will allow Glaukos to initiate a U.S. investigational new drug phase 2 study of a travoprost intraocular implant with the iDose delivery system in patients with glaucoma, according to a press release. “We are very pleased that the FDA is allowing this trial to begin several months in advance of our original target date,” Thomas Burns, president and CEO of Glaukos, said in the release.
Uncategorized
Research and Markets: Global Glaucoma Epidemiology and Patient Flow Analysis 2016
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/xjgjbd/global_glaucoma) has announced the addition of the “Global Glaucoma Epidemiology and Patient Flow Analysis – 2016” report to their offering. The report pro…
Proliferative Diabetic Retinopathy: New Data
The first large, prospective trial directly comparing panretinal photocoagulation with anti-VEGF treatment in this population may point to new treatment strategies. Medscape Ophthalmology
Uncategorized
pSivida to sell 4 million shares in public offering of common stock
pSivida plans to sell shares of its common stock at a public offering price of $4 per share, for gross proceeds of $16 million, in a proposed underwritten public offering of 4 million shares, according to a press release.The company has also granted an…